Progenics (PGNX) Said RELISTOR Clinical Trials Initiated in Japan
Up)
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced that its collaborator, Ono Pharmaceutical Co., Ltd., has begun clinical testing in Japan of RELISTOR subcutaneous injection, the first-in-class medicine approved in the U.S., Canada, the European Union, Australia and Latin American countries for the treatment of opioid-induced constipation.
Ono has exclusive rights to subcutaneous RELISTOR in Japan, where it is pursuing plans to develop and commercialize the drug, designated ONO-3849, for the treatment of opioid-induced constipation.
RELISTOR is being developed and commercialized in the rest of the world by Progenics and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE).
Ono has exclusive rights to subcutaneous RELISTOR in Japan, where it is pursuing plans to develop and commercialize the drug, designated ONO-3849, for the treatment of opioid-induced constipation.
RELISTOR is being developed and commercialized in the rest of the world by Progenics and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE).
You May Also Be Interested In
- Celldex (CLDX) volatility up into conference call to announce EMERGE results
- Pluristem (PSTI) CEO Aberman Sends Letter to Shareholders;
- Repros (RPRX) Gets Confirmation that Required Androxal Phase 3 Documents Delivered
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
